Fiore Marco, Ljevar Silva, Raut Chandraijt Premanand, Personeni Giulia, Rabih Mikhael, Gladdy Rebecca, Mercier Kelly, Sulciner Megan, Rossi Enrica, Tzanis Dimitri, Suraweera Harini, Colombo Chiara, Coppola Marianna, Bonvalot Sylvie, Iadecola Sara, Sarre-Lazcano Catherine, Figura Costanza, Salvatore Daniela, Miceli Rosalba, Gronchi Alessandro
Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: https://twitter.com/@FioreDoc.
Unit of Biostatistics for Clinical Research, Department Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Eur J Cancer. 2025 Jun 3;222:115474. doi: 10.1016/j.ejca.2025.115474. Epub 2025 Apr 30.
To evaluate desmoid fibromatosis (DF) progression and obstetric outcomes during and after pregnancy, providing evidence to inform clinical decision-making and counseling.
This international, multicenter, retrospective observational study included data from 157 women with DF, contributing 177 pregnancies. Women were classified into three groups: DF diagnosed during pregnancy (Group A), pregnancy occurring after the diagnosis of DF (Group B: DF in situ during pregnancy), or pregnancy in previously resected DF (Group C). Logistic regression and tumor size trend analyses were conducted.
Among 177 pregnancies, Group A exhibited the highest rates of DF progression (68.7 % during pregnancy, 40.6 % postpartum), while Groups B and C had lower progression rates (9.5 % during pregnancy, 8.3 % postpartum). Active treatment was required in 5.6 % of cases. Spontaneous regression occurred in 23.7 % of pregnancies, particularly following progression. Obstetric complications were comparable to those in the general population.
Pregnancy is generally safe for women with DF, particularly after prolonged disease stability. Individualized counseling is essential for managing risks of progression and recurrence, supporting informed fertility decisions. Referral to specialized centers is recommended to optimize DF management during family planning and pregnancy.
评估妊娠期间及产后韧带样纤维瘤病（DF）的进展情况及产科结局，为临床决策和咨询提供依据。
这项国际多中心回顾性观察研究纳入了157例DF女性患者的数据，共涉及177次妊娠。这些女性被分为三组：妊娠期间诊断为DF（A组）、DF诊断后妊娠（B组：妊娠期间DF原位）或既往已切除DF后的妊娠（C组）。进行了逻辑回归和肿瘤大小趋势分析。
在177次妊娠中，A组DF进展率最高（妊娠期间为68.7%，产后为40.6%），而B组和C组进展率较低（妊娠期间为9.5%，产后为8.3%）。5.6%的病例需要积极治疗。23.7%的妊娠出现自发消退，尤其是在进展之后。产科并发症与普通人群相当。
对于DF女性患者，妊娠总体上是安全的，尤其是在疾病长期稳定之后。个性化咨询对于管理进展和复发风险、支持明智的生育决策至关重要。建议转诊至专业中心，以优化计划生育和妊娠期间的DF管理。
